Evidence map›Paper›PMID 25285179›Full record

ReviewCurrent cardiovascular risk reports2014

Omega-3 Fatty Acid Blood Levels Clinical Significance Update.

H Robert Superko, Alex R Superko, Gina P Lundberg, Basil Margolis, Brenda C Garrett, Khurram Nasir, Arthur S Agatston

Abstract readReview
In one paragraph

Review in Current cardiovascular risk reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Omega-3 Fatty Acids May Prevent Sudden Unexpected Death in Epilepsy in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. Immunomodulatory Activities of Body Wall Fatty Acids Extracted fromJournal of microbiology and biotechnology · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Review
  18. Article
  19. Essential fatty acid deficiency during parenteral soybean oil lipid minimization.Journal of perinatology : official journal of the California Perinatal Association · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H Robert SuperkoCholesterol, Genetics, Heart Disease Institute, Mercer University School of Pharmaceutical Sciences, 40 Bear Paw, Portola Valley, CA 94028 USA.
Alex R SuperkoM3 Environmental, 1820 Vallejo St, Seaside, CA 93955 USA.
Gina P LundbergEmory Saint Joseph's Hospital, Emory University School of Medicine, 5673 Peachtree Dunwoody Rd, Atlanta, GA 30342 USA.
Basil MargolisEmory Saint Joseph's Hospital, Emory University School of Medicine, 5673 Peachtree Dunwoody Rd, Atlanta, GA 30342 USA.
Brenda C GarrettCholesterol, Genetics, Heart Disease Institute, 40 Bear Paw, Portola Valley, CA USA.
Khurram NasirBaptist Healthcare System, Florida State University School of Medicine, 1691 Michigan Ave. Suite 500, Miami, FL 33139 USA.
Arthur S AgatstonBaptist Healthcare System, Florida State University School of Medicine, 1691 Michigan Ave. Suite 500, Miami, FL 33139 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential benefit of fish oil (omega-3 fatty acids) consumption to reduce cardiovascular disease (CVD) risk remains controversial. Some investigations report reduced CVD risk associated with fish or fish oil consumption while others report no benefit. This controversy is in part resolved when consideration is given to omega-3 blood levels in relation to CVD risk as well as blood levels achieved in clinical trials of omega-3 supplementation and CVD benefit. There is a wide variation in omega-3 blood levels achieved between individuals in response to a given dose of an omega-3 supplement. Many studies tested a daily dose of 1 gram omega-3 supplementation. The individual variation in blood omega-3 levels achieved in response to a fixed daily dose helps to explain why some individuals may obtain CVD protection benefit while others do not due to failure to achieve a therapeutic threshold. Recent development of a population range in a United States population helps to provide clinical guidance since population omega-3 blood level ranges may vary due to environmental and genetic reasons. Omega-3 supplementation may also be of benefit in reducing the adverse impact of air pollution on CVD risk.

Indexed as

Blood measurementCardiovascular diseaseCoronary artery calciumDHADocosahexaenoic acidEicosapentaenoic acidEPAFish oilHeart diseaseMyocardial infarctionn-3 fatty acidn-3 PUFAOmega-3Polyunsaturated fatty acidPopulation distributionSudden death, Fatty acid

Identifiers

PMID25285179
PMCPMC4176556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.